PMID- 10915000
OWN - NLM
STAT- MEDLINE
DCOM- 20001130
LR  - 20191025
IS  - 0753-3322 (Print)
IS  - 0753-3322 (Linking)
VI  - 54 Suppl 1
DP  - 2000 Jun
TI  - Clinical aspects of hyperparathyroidism in Japanese multiple endocrine neoplasia 
      type 1.
PG  - 86s-89s
AB  - We describe here the clinical aspects of hyperparathyroidism (HP) in Japanese 
      multiple endocrine neoplasia type 1 (MEN 1). The total number of MEN 1 patients 
      was 37, and they originated from ten unrelated Japanese families. Nine of the ten 
      families were proven to have heterozygous germline mutations of the MEN 1 gene. 
      The incidence of HP, pituitary tumors, and pancreatic tumors in 37 MEN 1 patients 
      was 91.9%, 32.4%, and 45.9%, respectively. The age-related penetrances of HP were 
      50%, 79%, 84%, by 20, 30, and 40 years of age, respectively. Of these MEN 1 
      patients, we used 28 individuals, diagnosed with HP at our hospitals, to study 
      the clinical aspects of MEN 1-associated HP. The mean age was 40 years, and the 
      mean was much lower in the sporadic (non-MEN 1) HP patients. The mean levels of 
      calcium, phosphate, and intact PTH were 10.8 mg/dL, 2.3 mg/dL, and 178.0 pg/mL, 
      respectively, and these were not different from those of sporadic HP patients. 
      The levels of intact PTH were positively correlated with age, suggesting that HP 
      may be progressive with time in MEN 1. The percentage of symptomatic HP was 36% 
      in MEN 1, whereas it was 55% in sporadic HP patients. Although histopathological 
      findings revealed that all four parathyroid glands were involved in hyperplasia, 
      imaging studies showed an enlargement of only the single parathyroid gland in 
      most patients. The combination of total parathyroidectomy and autoplantation 
      succeeding in improving HP in MEN 1.
FAU - Sato, M
AU  - Sato M
AD  - First Department of Internal Medicine, Kagawa Medical University, Kita-gun, apan.
FAU - Miyauchi, A
AU  - Miyauchi A
FAU - Takahara, J
AU  - Takahara J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Parathyroid Hormone)
RN  - 971Z4W1S09 (Technetium Tc 99m Sestamibi)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Female
MH  - Genetic Testing
MH  - Humans
MH  - Hyperparathyroidism/blood/etiology/*physiopathology
MH  - Male
MH  - Multiple Endocrine Neoplasia Type 1/*complications
MH  - Parathyroid Hormone/blood
MH  - Technetium Tc 99m Sestamibi
EDAT- 2000/07/29 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/07/29 11:00
PHST- 2000/07/29 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/07/29 11:00 [entrez]
AID - S0753-3322(00)80020-7 [pii]
AID - 10.1016/s0753-3322(00)80020-7 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2000 Jun;54 Suppl 1:86s-89s. doi: 
      10.1016/s0753-3322(00)80020-7.